Search Results
Your search for ,are matches 21909 pages
Showing 1401 - 1450Highlights From the 2024 World Conference on Lung Cancer
At the 2024 World Conference on Lung Cancer (WCLC), more than 7,000 clinicians and scientists gathered in San Diego in celebration of the 50th anniversary of the International Association for the Study of Lung Cancer (IASLC). In this supplement to The ASCO Post, we review impactful abstracts from...
Participation in Virtual Prehabilitation and Outcomes Following Thoracic Cancer Surgery
Guest Editor’s Note: Oncology guidelines recommend prehabilitation exercises to minimize postoperative complications. However, the COVID-19 pandemic imposed severe restrictions on patient access to in-person exercise programs offered by hospitals and clinics. In this article, Dr. Krupali Desai...
NCCN Guidelines Have Expanded to Meet Growing Understanding of Hereditary Risk
The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers. The new guidelines followed the recent...
Study Explores Underpinnings of Immunotherapy-Releated Myocarditis in Patients With Cancer
Researchers may have uncovered the immune basis for the development of myocarditis in patients with cancer receiving immune checkpoint inhibitors, according to a recent study published by Blum et al in Nature. The findings revealed changes in specific types of immune and stromal cells in the heart...
SITC: Study Finds IO102-IO103 Vaccine Plus Pembrolizumab Active in Patients With Non–Small Cell Lung Cancer
A phase II study by Riess et al investigating the IO102-IO103 vaccine plus pembrolizumab as first-line treatment in patients with non–small cell lung cancer (NSCLC) showed “promising” overall response rates and 6-month progression-free survival, with an acceptable safety profile. The study...
Neoadjuvant Therapy Yields Notable Outcomes in Triple-Negative Breast Cancer
The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors. For comprehensive news of these studies and more, visit ASCOPost.com. Triple-Negative Breast Cancer: Phase III KEYNOTE-522 The phase III KEYNOTE-522 trial has...
NCI Grant May Facilitate Development of Breast CT Screening Technology
The University of Arizona Health Sciences announced it has received a $3.3 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to continue testing a novel imaging method for breast cancer detection that could provide an alternative to mammography. According...
Breast Cancer in 2024: Looking Back and Moving Forward
In a recent issue of The New York Times, Barron Lerner discussed Betty Ford’s breast cancer diagnosis in 1974.1 He described the state of the art of breast cancer treatment at the time and how her diagnosis accelerated the uptake of screening across the country. But her cancer was not...
Researchers May Have Uncovered Why Some AML Cells Resist Treatment
Researchers have provided new insights into acute myeloid leukemia (AML) and its resistance to venetoclax, according to a recent study published by Sango et al in Nature. Although AML is a rare disease, approximately 20,800 U.S. patients will be diagnosed in 2024, according to the American Cancer...
How Hypoxia May Help Cancer Metastasize
Researchers have identified genes that breast cancer cells may use to survive in the bloodstream after escaping the low-oxygen regions of a tumor, according to a novel study published by Godet et al in Nature Communications. Each of the genes may serve as a potential therapeutic target to prevent...
A Diagnosis of Lymphoma Has Changed My Life
I’m 50, just a year older than my father was when he died of colorectal cancer. I was 14 when my dad died, so to me, cancer has always been synonymous with death. From a young age, my brothers and I had a goal: to make sure we packed in enough life before age 50. It never occurred to us that death ...
From Gaps to Bridges: Cancer Care Rooted in Equity, Quality, and Value
“Inequities are a major obstacle in delivering safe, timely, respectful, and affordable cancer care globally,” commented moderator John Varallo, MD, MPH, FACOG, of the Global Surgery Foundation, at the Union for International Cancer Control (UICC) World Cancer Congress (WCC) 2024 in Geneva.1...
Study Finds Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost
The alternative use of the monoclonal antibody cetuximab during the shortage of cisplatin in the treatment of head and neck cancer resulted in a 16% total cost increase, leading to a 144-fold increase in costs at the administrative level, impacting payer costs and patient cost-sharing amounts....
18 Researchers and Mentors Selected for ASCO’s Inaugural International Clinical Research Scholars Program in Latin America
ASCO has announced the participants and mentors selected for its new International Clinical Research Scholars (ICR) program. Eighteen scholars were selected by the ASCO Latin America Regional Council to take part in this 1-year program that pairs clinical research training with mentorship...
Physician Wellness and Professional Burnout
According to an ASCO-sponsored study of burnout and career satisfaction among U.S. oncologists, 44.7% of surveyed oncologists reported feeling symptoms of burnout. ASCO offers information, practical advice, and member perspectives on how to prevent and manage burnout and prioritize wellness in your ...
Tarlatamab-dlle for Previously Treated Extensive-Stage SCLC
On May 16, 2024, tarlatamab-dlle (Imdelltra) was granted accelerated approval for extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.1 Tarlatamab is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T-cell engager. Supporting Efficacy...
Risk of Second Primary Cancers After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers
In an English study reported in the Journal of Clinical Oncology, Allen et al found that patients with breast cancer harboring BRCA1/BRCA2 pathogenic variants were at high risk of second primary cancers. Study Details and Results The study involved follow-up of 25,811 females and 480 males...
$2.5 Million Grant May Help Increase Lung Cancer Screenings in Underserved Communities
Researchers from the Health Jonsson Comprehensive Cancer Center, the David Geffen School of Medicine, and the Fielding School of Public Health at the University of California, Los Angeles (UCLA) were awarded a $2.5 million grant from the independent charitable organization Bristol Myers Squibb...
Unexpected Results in Solid Tumors: What We Learned From Negative Findings
Attendees at the European Society for Medical Oncology (ESMO) Congress 2024 heard the results of many positive clinical trials that will advance the field of cancer treatment. However, a few late-stage trials of promising adjuvant therapies unexpectedly reported negative results. The ASCO Post...
Durvalumab Plus Chemotherapy Improves Overall Survival in Localized Muscle-Invasive Bladder Cancer
The addition of the PD-L1 inhibitor durvalumab to standard neoadjuvant gemcitabine/cisplatin chemotherapy has demonstrated statistically significant and clinically meaningful improvements in survival compared with neoadjuvant chemotherapy in cisplatin-eligible patients with muscle-invasive bladder...
When Cancer and Cardiovascular Disease Intersect
The annual Global Cardio-Oncology Summit (GCOS) was held September 22 to 24 in Minneapolis, with 430 health-care professionals attending from 20 countries. The Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology...
Eyeing the Future of Oncology: Highlights From the Presidential Symposium at ESMO Congress 2024
At the European Society for Medical Oncology (ESMO) Congress 2024, the Eyes to the Future Presidential Symposium showcased innovative approaches in personalized medicine, immunotherapy resistance, and artificial intelligence (AI)-driven pathology analysis. These presentations, focusing on the...
Evolving Role of MRD Status in Multiple Myeloma
The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in...
Jennifer Bickel, MD, Named MD Anderson Vice President and Chief Wellness Officer
The University of Texas MD Anderson Cancer Center recently announced the selection of Jennifer Bickel, MD, as the institution’s inaugural Vice President and Chief Wellness Officer (CWO). She will assume this role on January 6, 2025. Working closely with the Shibu Varghese, MA, Senior Vice...
Immunotherapy Combination May Demonstrate Benefit in Patients With Cutaneous Melanoma
Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve tumor control in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings provided insights that could help advance...
Novel Method for Liquid Biopsies May Streamline Cancer Detection
Researchers have discovered a novel strategy to detect cancer cells with a liquid biopsy designed to be simpler, quicker, and more informational compared with current methods, according to a recent study published by Walker et al in Small. Background Current methods for detecting cancer cells may...
Quantifying the Benefit of Smoking Cessation Within 6 Months of a Cancer Diagnosis
Quitting smoking within 6 months of receiving a cancer diagnosis could add an average of 2 years to a patient’s life, according to a recent study published by Cinciripini et al in JAMA Oncology. The findings demonstrated a broad survival benefit of using evidence-based smoking cessation to help...
NCCN Harmonized Guidelines for Sub-Saharan Africa: Experts Convene in Ghana to Update Cancer Treatment Guidelines
An international team of oncology experts gathered in Accra, Ghana, for a series of meetings to update cancer treatment recommendations in the National Comprehensive Cancer Network (NCCN) Harmonized Guidelines for Sub-Saharan Africa. Background The NCCN Harmonized Guidelines offer color-coded tiers ...
How End-of-Life Dreams and Visions Are Bringing Comfort to Dying Patients
Just weeks or even days or hours away from death, the majority of conscious terminally ill patients often experience growth and meaning in their lives and the absence of fear through end-of-life dreams and visions, according to research by Christopher W. Kerr, MD, PhD. Dr. Kerr is Chief Executive...
CDK4/6 Inhibition in Peritoneal Mucinous Carcinomatosis With GNAS Mutation
In a single-institution study reported in the Journal of Clinical Oncology, Weitz et al found that the CDK4/6 inhibitor palbociclib was active as a novel treatment in patients with peritoneal mucinous carcinomatosis with GNAS mutation. As stated by the investigators: “Mucinous neoplasms of the...
Weighing Blood-Based vs Standard Colorectal Cancer Screening Options
Because colonoscopies and more established stool-based tests are more effective at detecting early cancers and precancerous polyps compared with emerging blood-based tests, their long-term impact is projected to be substantially greater than that of blood-based tests, according to a recent study...
Using AI to Measure Prostate Cancer Lesions Could Aid Diagnosis and Treatment
Researchers have trained and validated an artificial intelligence (AI) model based on magnetic resonance imaging (MRI) scans to develop a consistent method of estimating prostate cancer lesion size, according to a recent study published by Yang et al in Radiology. The findings could aid physicians...
TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC
The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...
Lung Cancer Screening Model May Remove Barriers for Vulnerable Patients Residing in Central Texas
A new lung cancer screening initiative may help to overcome barriers to care among low-income, uninsured, and minority patients residing in Central Texas, according to a recent study published by Pignone et al in the American Journal of Preventive Medicine. The findings represented a critical step...
New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
Using computational tools, researchers have developed a novel method to assess which patients with metastatic triple-negative breast cancer may benefit from immunotherapy, according to a recent study published by Arulraj et al in the Proceedings of the National Academy of Sciences (PNAS)....
Use of Aumolertinib Extends Progression-Free Survival in Stage III EGFR-Mutated NSCLC
Aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, has shown efficacy as maintenance therapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to data presented at the International Association for the Study of Lung Cancer...
FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to the BCR::ABL1 kinase inhibitor asciminib (Scemblix) for adult patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph-positive CML) in chronic phase. The FDA approval was granted on...
Ensuring an Inclusive Environment for Female Minority Oncologists
ASCO’s 2022 State of the Oncology Workforce in America report presented a dismal picture of the representation of Hispanic/Latinx oncologists in the field. According to the report, despite initiatives aimed at increasing diversity in the nearly 13,400 oncology workforce, which includes about 36%...
Distant Recurrence Risk Among Women With Early Breast Cancer Enrolled in Clinical Trials Between 1990 and 2009: EBCTCG Analysis
In an analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) reported in The Lancet, Hills et al found that risk of distant recurrence declined over time among women with early breast cancer enrolled in clinical trials between 1990 and 2009. Study Details The pooled analysis...
Medicaid Expansion May Improve Cancer Care, Survival Among Patients With Hormone Receptor–Negative, HER2-Positive Breast Cancer
Patients with newly diagnosed hormone receptor–negative, HER2-positive breast cancer were more likely to receive timely, guideline-concordant treatment and experience longer survival in states participating in Medicaid expansion under the Affordable Care Act, according to a recent study published...
New Marker for Immunotherapy Response in Hepatocellular Carcinoma
A newly described stage of lymph node–like structures, known as tertiary lymphoid structures, identified in hepatic tumors following presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a recent study published by Shu et al in Nature...
Scientists Develop a ‘Digital Twin’ Model to Predict Cancer Treatment Responses
Researchers have created a “digital twin” model constructed from the clinical and molecular profiles of patients with cancer that accurately predicted how a patient is likely to respond to a specific chemotherapy. The approach optimizes the treatment choice for patients using available clinical...
Early Results Show Novel Agent Has Clinical Activity in FGFR3-Driven Advanced Bladder Cancer
In a phase I clinical trial (SURF301) investigating the fibroblast growth factor receptor 3 (FGFR3) oral inhibitor TYRA-300 in patients with advanced bladder cancer, the drug showed early antitumor activity and produced lower rates of significant adverse events compared with pan-FGFR inhibitors....
Immunotherapy Plus Targeted Therapy for Anaplastic Thyroid Carcinoma
Researchers have demonstrated that anti–PD-L1 immunotherapy combined with mutation-directed targeted therapy may improve overall survival in patients with anaplastic thyroid carcinoma, according to a recent study published by Cabanillas et al in JAMA Oncology. Background Anaplastic thyroid...
ECOG-ACRIN Cancer Research Group, Caris Life Sciences Partner to Learn More From TAILORx Trial
The ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a new multiyear research collaboration that will begin with the interrogation of the TAILORx trial. Background Breast cancer remains the most common cancer type in the United States, with approximately 310,720 new cases per...
Mutations and DNA Structures May Drive Urothelial Carcinoma
Researchers may have uncovered how urothelial carcinoma originates and progresses, according to a novel study published by Nguyen et al in Nature. The findings provided insights into the biology of urothelial carcinoma and may point to new therapeutic strategies for this difficult-to-treat cancer...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting. Background Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science,...
My Melanoma Could Have Been Prevented
I have many of the risk factors for melanoma. I’m fair-skinned, blue-eyed, and have a family history of melanoma, as well as other skin cancers, so I’ve always been diligent about practicing sun safety and maintaining annual full-body skin exams to catch any suspicious moles or lesions that could...
Whole-Person Cancer Care: A Transformative Vision for Oncology
Guest Editor’s Note: Advances in cancer treatments have led to an increase in survival rates, but the quality of life is often diminished during survivorship. Because modifiable personal behavior contributes to health-care outcomes, interventions that support healthy behaviors may improve health...
I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and “all-negative” subtypes.1...
